What Medicare price benchmark does BEQIA face against Eliquis?
For 2026, Medicare’s negotiated price for a 30-day Eliquis (apixaban) supply is US$231, compared with the 2023 list price of US$521, a rounded 56% reduction. Drugnews’s November 5, 2026 analysis uses this CMS benchmark to discuss the pricing environment for TAHO Pharmaceuticals’ BEQIA oral film; the figures do not set BEQIA’s own price.
The comparison is not a discount from a current net price, a retail cash quote, or a proposed BEQIA price.
Sources
Read the full analysis
TAHO Doubles in Two Weeks, but a Court Holds Its US Clock — 2026-11-05